Apatinib structure
|
Common Name | Apatinib | ||
---|---|---|---|---|
CAS Number | 811803-05-1 | Molecular Weight | 397.472 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 578.2±50.0 °C at 760 mmHg | |
Molecular Formula | C24H23N5O | Melting Point | N/A | |
MSDS | N/A | Flash Point | 303.5±30.1 °C |
Use of ApatinibApatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the treatment of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[1][2][3]. |
Name | 3-Pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]- |
---|---|
Synonym | More Synonyms |
Description | Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the treatment of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[1][2][3]. |
---|---|
Related Catalog | |
Target |
IC50: 1 nM (VEGFR-2), 13 nM (Ret), 429 nM (c-Kit), 530 nM (c-Src)[3] |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 578.2±50.0 °C at 760 mmHg |
Molecular Formula | C24H23N5O |
Molecular Weight | 397.472 |
Flash Point | 303.5±30.1 °C |
Exact Mass | 397.190247 |
PSA | 90.70000 |
LogP | 3.68 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.652 |
Apatinib |
N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide |
3-Pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]- |
YN968D1 |